Prognostic significance of angiogenesis in relation to Ki-67, p-53, p-27, and bcl-2 expression in embryonal tumors

Pediatric Neurosurgery

Volumn 47, Issue 4, 2011, Pages 241-247

  Moschovi, Maria ^a   Koultouki, Eleutheria ^a   Stefanaki, Kalliopi ^b   Sfakianos, George ^b   Tourkantoni, Natalia ^a   Prodromou, Neofytos ^b   Alexiou, George A ^b,c  

^a UNIVERSITY OF ATHENS   (Greece)

^b AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

^c NONE   (Greece)

Author keywords

Angiogenesis; Atypical teratoid rhabdoid tumor; Ki 67; Medulloblastoma; p 27; p 53

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; KI 67 ANTIGEN; METHOTREXATE; PROTEIN BCL 2; PROTEIN P27; PROTEIN P53; VINCRISTINE;

ADOLESCENT; ANGIOGENESIS; ARTICLE; BENIGN TUMOR; BLOOD VESSEL; CANCER CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; DENSITY; EMBRYONAL TUMOR; FEMALE; HUMAN; MALE; MEDULLOBLASTOMA; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; RHABDOID TUMOR; SCHOOL CHILD; TERATOMA;

EID: 84861099400     PISSN: 10162291     EISSN: 14230305     Source Type: Journal    
DOI: 10.1159/000335398     Document Type: Article

References (36)

1. Gottardo NG, Gajjar A: Chemotherapy for malignant brain tumors of childhood. J Child Neurol 2008; 23: 1149-1159.
2. Monteith SJ, Heppner PA, Woodfield MJ, Law AJ: Paediatric central nervous system tumours in a New Zealand population: A 10-year experience of epidemiology, management strategies and outcomes. J Clin Neurosci 2006; 13: 722-729.
3. Gajjar A, Chintagumpala M, Ashley D, et al: Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stemcell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): Long-term results from a prospective, multicentre trial. Lancet Oncol 2006; 7: 813-820.
4. Moschovi M, Alexiou GA, Patereli A, et al: Prognostic significance of cyclin A and B1 in pediatric embryonal tumors. J Neurooncol 2011; 103: 699-704.
5. Alexiou GA, Moschovi M, Stefanaki K, et al: Epidemiology of pediatric brain tumors in Greece (1991-2008): Experience from the Agia Sofia Children's Hospital. Cen Eur Neurosurg 2011; 72: 1-4.
6. Bellil S, Limaiem F, Mahfoudhi H, Bellil K, Chelly I, Mekni A, Jemel H, Khaldi M, Haouet S, Zitouna M, Kchir N: Descriptive epidemiology of childhood central nervous system tumours in Tunisia: Experience of a single institution over a 15-year period (1990-2004). Pediatr Neurosurg 2008; 44: 382-387.
7. Northcott PA, Korshunov A, Witt H, et al: Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 2011; 29: 1408-1414.
8. de Haas T, Hasselt N, Troost D, et al: Molecular risk stratification of medulloblastoma patients based onimmunohistochemical analysis of MYC, LDHB, and CCNB1 expression. Clin Cancer Res 2008; 14: 4154-4160.
9. Tural S, Gercek A, Konya D, Ozgen S, Toplamoglu H, Ozek MM: Microvessel density and vascular endothelial growth factor expression as predictors of children's survival from cerebellar medulloblastoma. J Clin Neurosci 2009; 16: 1199-1202.
10. Ellison DW, Kocak M, Dalton J, et al: Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. J Clin Oncol 2011; 29: 1400-1407.
11. Packer RJ, Gajjar A, Vezina G, et al: Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 2006; 24: 4202-4208.
12. Folkman J: Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29: 15-18.
13. Louis DN, Ohgaki H, Wiestler OD, et al: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114: 97-109.
14. Pusztaszeri MP, Seelentag W, Bosman FT: Immunohistochemical expression of endothelial markers CD31, CD34, von Willebrand factor, and Fli-1 in normal human tissues. J Histochem Cytochem 2006; 54: 385-395.
15. Forsythe JA, Jiang BH, Iyer NV, et al: Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996; 16: 4604-4413.
16. Carmeliet P, Dor Y, Herbert JM, et al: Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998; 394: 485-490.
17. Ray A, Ho M, Ma J, et al: A clinicobiological model predicting survival in medulloblastoma. Clin Cancer Res 2004; 10: 7613-7620.
18. Ellison D: Classifying the medulloblastoma: Insights from morphology and molecular genetics. Neuropathol Appl Neurobiol 2002; 28: 257-282.
19. Tabori U, Baskin B, Shago M, et al: Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations. J Clin Oncol 2010; 28: 1345-1350.
20. Pfaff E, Remke M, Sturm D, et al: TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma. J Clin Oncol 2010; 28: 5188-5196.
21. Quinones-Hinojosa A, Sanai N, Smith JS, McDermott MW: Techniques to assess the proliferative potential of brain tumors. J Neurooncol 2005; 74: 19-30.
22. Ho DM, Hsu CY, Wong TT, Ting LT, Chiang H: Atypical teratoid/rhabdoid tumor of the central nervous system: A comparative study with primitive neuroectodermal tumor/medulloblastoma. Acta Neuropathol 2000; 99: 482-488.
23. Ertan Y, Sezak M, Demirag B, et al: Medulloblastoma: Clinicopathologic evaluation of 42 pediatric cases. Childs Nerv Syst 2009; 25: 353-356.
24. Miralbell R, Tolnay M, Bieri S, et al: Pediatric medulloblastoma: Prognostic value of p53, bcl-2, Mib-1, and microvessel density. J Neurooncol 1999; 45: 103-110.
25. Nam DH, Wang KC, Kim YM, Chi JG, Kim SK, Cho BK: The effect of isochromosome 17q presence, proliferative and apoptotic indices, expression of c-erbB-2, bcl-2 and p53 proteins on the prognosis of medulloblastoma. J Korean Med Sci 2000; 15: 452-456.
26. Meurer RT, Martins DT, Hilbig A, et al: Immunohistochemical expression of markers Ki-67, neun, synaptophysin, p53 and HER2 in medulloblastoma and its correlation with clinicopathological parameters. Arq Neuropsiquiatr 2008; 66: 385-390.
27. Patereli A, Alexiou G, Stefanaki K, et al: Expression of epidermal growth factor and receptor and HER-2 in pediatric embryonal brain tumors. Pediatr Neurosurg 2010; 46: 188-192.
28. Lloyd RV, Erickson LA, Jin L, et al: P27kip1: A multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers Am J Pathol 1999; 154: 313-323.
29. Adesina AM, Dunn ST, Moore WE, Nalbantoglu J: Expression of p27kip1 and p53 in medulloblastoma: Relationship with cell proliferation and survival. Pathol Res Pract 2000; 196: 243-250.
30. Das P, Puri T, Suri V, Sharma MC, Sharma BS, Sarkar C: Medulloblastomas: A correlative study of MIB-1 proliferation index along with expression of c-Myc, ERBB2, and antiapoptotic proteins along with histological typing and clinical outcome. Childs Nerv Syst 2009; 25: 825-835.
31. Schiffer D, Cavalla P, Migheli A, et al: Bcl-2 distribution in neuroepithelial tumors: An immunohistochemical study. J Neurooncol 1996; 27: 101-109.
32. Schüller U, Schober F, Kretzschmar HA, Herms J: Bcl-2 expression inversely correlates with tumour cell differentiation in medulloblastoma. Neuropathol Appl Neurobiol 2004; 30: 513-521.
33. Krajewski S, Krajewska M, Ehrmann J, et al: Immunohistochemical analysis of Bcl-2, Bcl-X, Mcl-1, and Bax in tumors of central and peripheral nervous system origin. Am J Pathol 1997; 150: 805-814.
34. Onvani S, Etame AB, Smith CA, Rutka JT: Genetics of medulloblastoma: Clues for novel therapies. Expert Rev Neurother 2010; 10: 811-823.
35. Nord H, Pfeifer S, Nilsson P, et al. Novel amplifications in pediatric medulloblastoma identified by genome-wide copy number profiling. J Neurooncol 2011 Oct 7. [Epub ahead of print].
36. Pfister S, Remke M, Benner A, et al: Outcome prediction in pediatric medulloblastomas based on DNA copy number aberrations of chromosomes 6q and 17q and MYC and MYCN loci. J Clin Oncol 2009; 27: 1627-1636.